Biocryst Pharmaceuticals, Inc. · NASDAQ:BCRX
Biocryst Pharmaceuticals — Corporate Update (December 2012)
7 slides from Biocryst Pharmaceuticals's corporate update, Dec 7, 2012
Slide 1: BioCryst Strategy & Restructuring Update
Exhibit 99.2 BioCryst Strategy & Restructuring Update December 7, 2012
Slide 2: Forward-looking statement
Forward-looking statement BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertaint
Slide 3: Path forward to rebuild shareholder value
Path forward to rebuild shareholder value Restructure & focus Invest primarily in three core programs Oral hereditary angioedema treatments/BCX4161 and next generation molecule Hemorrhagic fevers/broad spectrum antiviral BCX4430 HCV antiviral/BCX5191 Restructuring goals: Scale organization appropria
Slide 4: BioCryst's pipeline
BioCryst’s pipeline Inflammatory Disease Preclinical Phase 1 Phase 2 Pivotal Filed Approved Ulodesine (Gout) BCX4161 (Hereditary angioedema) Infectious Disease Preclinical Phase 1 Phase 2 Pivotal Filed Approved Peramivir Outpatient Flu¹ (Seasonal influenza / i.v.) Peramivir Inpatient Flu (Acute infl
Slide 5: Financial impact of corporate restructuring
Financial impact of corporate restructuring Recent setbacks in the peramivir & BCX5191 programs, as well as the delay in the BCX4161 program, necessitate a significant reduction in BioCryst’s cost structure Significant operating expense reductions provide a 38-45% Reduction of 38 positions (50%) in
Slide 6: Implications of restructuring & preliminary guidance
Implications of restructuring & preliminary guidance* (in millions) Cash & investments as of December 31, 2012 $35 –37 Restructuring charge (2012) $2 –4 Deal charge (2012) $1 –2 2012 cash utilization + $40 2013 cash utilization + $22 –25 Months of cash runway from January 1, 2013 15 –18 *Preliminary
Slide 7: Milestones though mid-2014
Milestones though mid-2014 Program Milestones Begin Phase 1 trial BCX4161 Complete Phase 1 (Hereditary angioedema) Start trial in HAE patients Begin preclinical development Next gen HAE compound File IND Publish filovirus animal proof of concept data BCX4430 Secure government funding for development
BioCryst Pharmaceuticals — Corporate Update (December 2012) on 6ix